wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35157497-0BDF11B3-E3BD-4505-BD2C-2B65989D00B9
Q35157497-0BDF11B3-E3BD-4505-BD2C-2B65989D00B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35157497-0BDF11B3-E3BD-4505-BD2C-2B65989D00B9
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
P2860
Q35157497-0BDF11B3-E3BD-4505-BD2C-2B65989D00B9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35157497-0BDF11B3-E3BD-4505-BD2C-2B65989D00B9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
80675bed0854e31e0ecb196e287c4d3ba12c932e
P2860
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.